TrialCancer medicine2022

Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: Phase 2 study.

Nicolas Boissel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.